Credentialing
Southwest OncologyGroup (SWOG) |
|||||||
|
|||||||
|
|||||||
S1001 | - |
A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse
Large B-cell Lymphoma (DLBCL) - Closed (effective 6/19/2017)
|
|||||
S1206 | - |
A Dose Finding Study Followed by Phase II Randomized,
Placebo-Controlled Study of Veliparib (ABT-888) Added to
Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable
Stage III Non-Small Cell Lung Cancer (NSCLC), (NCI Study Number
8811) - Closed (effective 10/23/2017)
|
|||||
S1619 | - |
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
|
SWOG S1206 Requirements
Institutions that were previously credentialed to participate in another protocol or have a question about your status for this protocol, please fill out the credentialing status inquiry form.
This study requires credentialing. The credentialing requirements are different depending on whether you are using a 3DCRT or IMRT technique. You can be credentialed for either 3DCRT or IMRT or both depending on your physician’s preference.
3D credentialing:
• Must complete and submit to IROC Houston the 3D Conformal Benchmark
IMRT credentialing:
• Must complete and submit to IROC Houston the IMRT Facility Questionnaire.
• Irradiate the IROC Houston's IMRT H&N phantom.2 Please fill in the phantom request form online.
OR
• Complete and submit the IMRT Benchmark to IROC Houston
• If an institution is using IMRT with gating or tracking, the institution must irradiate IROC Houston’s lung phantom with motion platform. Please fill in the phantom request form online.
• If techniques are used to compensate for or limit respiratory motion the IROC Houston questionnaire on respiratory motion management must be submitted to IROC Houston.